Takeda Pharmaceutical (TAK) Short-term Investments (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Short-term Investments of $2.9 billion for Q2 2026, up 24.7% year-over-year from $2.3 billion in Q2 2025, and up 3.58% quarter-over-quarter from $2.8 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Short-term Investments (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Short-term Investments history runs 10 years deep, the most recent figure standing at $2.9 billion for Q2 2026.
- In Q2 2026, Short-term Investments rose 24.7% year-over-year to $2.9 billion; the TTM figure through Jun 2026 stood at $2.9 billion (up 24.7% YoY), while the FY2026 annual figure was $2.9 billion, up 2074.21% from the prior year.
- Short-term Investments for Q2 2026 stood at $2.9 billion, up from $2.8 billion in the prior quarter.
- The five-year high for Short-term Investments was $2.9 billion in Q2 2026, with the low at $101.8 million in Q1 2024.
- The 5-year median for Short-term Investments is $2.2 billion (2022), against an average of $1.8 billion.
- The sharpest annual moves came in 2022 and 2026: Short-term Investments slumped 37.02% in 2022, then jumped 1990.2% in 2026.
- Takeda Pharmaceutical's Short-term Investments stood at $1.9 billion in 2022, then retreated by 6.31% to $1.8 billion in 2023, then jumped by 43.36% to $2.6 billion in 2024, then climbed by 5.36% to $2.8 billion in 2025, then grew by 5.47% to $2.9 billion in 2026.
- Business Quant data shows TAK's Short-term Investments at $2.9 billion in Q2 2026, $2.8 billion in Q1 2026, and $2.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.91 Bn |
| Mar 31, 2026 | 2.81 Bn |
| Dec 31, 2025 | 2.75 Bn |
| Sep 30, 2025 | 2.48 Bn |
| Jun 30, 2025 | 2.33 Bn |
| Mar 31, 2025 | 134.21 Mn |
| Dec 31, 2024 | 2.61 Bn |
| Sep 30, 2024 | 1.75 Bn |
| Jun 30, 2024 | 2.31 Bn |
| Mar 31, 2024 | 101.82 Mn |
| Dec 31, 2023 | 1.82 Bn |
| Sep 30, 2023 | 2.17 Bn |
| Jun 30, 2023 | 2.14 Bn |
| Mar 31, 2023 | 152.51 Mn |
| Dec 31, 2022 | 1.95 Bn |
| Sep 30, 2022 | 2.38 Bn |
| Jun 30, 2022 | 2.20 Bn |
| Mar 31, 2022 | 217.75 Mn |
| Dec 31, 2021 | 2.03 Bn |
| Sep 30, 2021 | 2.15 Bn |